Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 Years
Background - Benralizumab is an IL-5Rα-directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma. - Objective - To evaluate the long-term safety and tolerability of benralizumab among adults treated for up to 5 years. - Methods - This analysis included adults...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
7 December 2021
|
| In: |
The journal of allergy and clinical immunology. In practice
Year: 2021, Volume: 9, Issue: 12, Pages: 1-16 |
| ISSN: | 2213-2201 |
| DOI: | 10.1016/j.jaip.2021.07.058 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jaip.2021.07.058 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2213219821009685 
|
| Author Notes: | Stephanie Korn, MD, Arnaud Bourdin, MD, PhD, Geoffrey Chupp, MD, Borja G. Cosio, MD, PhD, Doug Arbetter, MPH, Mihir Shah, MD, and Esther Garcia Gil, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1818574284 | ||
| 003 | DE-627 | ||
| 005 | 20240326080203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221011s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2021.07.058 |2 doi | |
| 035 | |a (DE-627)1818574284 | ||
| 035 | |a (DE-599)KXP1818574284 | ||
| 035 | |a (OCoLC)1361713993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Korn, Stephanie |d 1980- |e VerfasserIn |0 (DE-588)131754483 |0 (DE-627)513603298 |0 (DE-576)298718855 |4 aut | |
| 245 | 1 | 0 | |a Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 Years |c Stephanie Korn, MD, Arnaud Bourdin, MD, PhD, Geoffrey Chupp, MD, Borja G. Cosio, MD, PhD, Doug Arbetter, MPH, Mihir Shah, MD, and Esther Garcia Gil, MD |
| 264 | 1 | |c 7 December 2021 | |
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.10.2022 | ||
| 520 | |a Background - Benralizumab is an IL-5Rα-directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma. - Objective - To evaluate the long-term safety and tolerability of benralizumab among adults treated for up to 5 years. - Methods - This analysis included adults treated with placebo or subcutaneous benralizumab 30 mg every 4 or 8 weeks in the 48-week SIROCCO, 56-week CALIMA, and 28-week ZONDA pivotal trials, who were subsequently enrolled in the 56-week double-blind BORA extension and continued assigned regimens or initiated benralizumab (if previously on placebo) for 16 to 40 weeks, before entering the open-label MELTEMI extension. Safety was measured by adverse and serious adverse event rates. Exacerbations were evaluated in patients with blood eosinophils greater than or equal to 300 cells/μL receiving high-dose inhaled corticosteroids at baseline. - Results - Overall, 446 received treatment and 384 (86.1%) completed the study; 157 (35.2%) received benralizumab for 4 or more years. Adverse and serious adverse event rates (28.5-32.4 and 6.3-8.4 per 100 patient-years, respectively) were low, stable over time, and did not increase with exposure; few (n = 8) discontinued because of adverse events. Serious infections and hypersensitivity event rates were consistent with those in previous studies. Among patients with blood eosinophils greater than or equal to 300 cells/μL-high-dosage inhaled corticosteroids receiving benralizumab every 8 weeks, at least 75% had zero exacerbations annually during the integrated analysis period. - Conclusions - In patients with severe, uncontrolled eosinophilic asthma, long-term benralizumab was safe and well tolerated for up to 5 years. There were no new safety signals, and exacerbations were eliminated in similar percentages of patients as in predecessor studies. | ||
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Benralizumab | |
| 650 | 4 | |a Eosinophils | |
| 650 | 4 | |a Exacerbation | |
| 650 | 4 | |a Integrated analysis | |
| 700 | 1 | |a Bourdin, Arnaud |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chupp, Geoffrey |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cosio, Borja G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arbetter, Doug |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shah, Mihir |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gil, Esther Garcia |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d Amsterdam [u.a.] : Elsevier, 2013 |g 9(2021), 12, Artikel-ID 4381-4392.e4, Seite 1-16 |h Online-Ressource |w (DE-627)757132758 |w (DE-600)2728366-5 |w (DE-576)392331748 |x 2213-2201 |7 nnas |a Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 Years |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:12 |g elocationid:4381-4392.e4 |g pages:1-16 |g extent:16 |a Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 Years |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jaip.2021.07.058 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2213219821009685 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221011 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 131754483 |a Korn, Stephanie |m 131754483:Korn, Stephanie |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK131754483 |e 950000PK131754483 |e 950900PK131754483 |e 50000PK131754483 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1818574284 |e 4196039324 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 Years","title_sort":"Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 Years"}],"person":[{"family":"Korn","given":"Stephanie","roleDisplay":"VerfasserIn","display":"Korn, Stephanie","role":"aut"},{"role":"aut","display":"Bourdin, Arnaud","roleDisplay":"VerfasserIn","given":"Arnaud","family":"Bourdin"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Chupp, Geoffrey","given":"Geoffrey","family":"Chupp"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Cosio, Borja G.","given":"Borja G.","family":"Cosio"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Arbetter, Doug","given":"Doug","family":"Arbetter"},{"display":"Shah, Mihir","roleDisplay":"VerfasserIn","role":"aut","family":"Shah","given":"Mihir"},{"role":"aut","display":"Gil, Esther Garcia","roleDisplay":"VerfasserIn","given":"Esther Garcia","family":"Gil"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 11.10.2022"],"recId":"1818574284","language":["eng"],"origin":[{"dateIssuedDisp":"7 December 2021","dateIssuedKey":"2021"}],"id":{"doi":["10.1016/j.jaip.2021.07.058"],"eki":["1818574284"]},"name":{"displayForm":["Stephanie Korn, MD, Arnaud Bourdin, MD, PhD, Geoffrey Chupp, MD, Borja G. Cosio, MD, PhD, Doug Arbetter, MPH, Mihir Shah, MD, and Esther Garcia Gil, MD"]},"physDesc":[{"extent":"16 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2213-2201"],"eki":["757132758"],"zdb":["2728366-5"]},"origin":[{"dateIssuedKey":"2013","publisher":"Elsevier","dateIssuedDisp":"2013-","publisherPlace":"Amsterdam [u.a.]"}],"recId":"757132758","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Integrated safety and efficacy among patients receiving Benralizumab for Up to 5 YearsThe journal of allergy and clinical immunology. In practice","note":["Gesehen am 13.12.13"],"titleAlt":[{"title":"The journal of allergy and clinical immunology / In practice"}],"part":{"text":"9(2021), 12, Artikel-ID 4381-4392.e4, Seite 1-16","volume":"9","extent":"16","year":"2021","issue":"12","pages":"1-16"},"pubHistory":["1.2013 -"],"title":[{"partname":"In practice","title":"The journal of allergy and clinical immunology","title_sort":"journal of allergy and clinical immunology"}]}]} | ||
| SRT | |a KORNSTEPHAINTEGRATED7202 | ||